MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412209 | Name: Darsidomine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Darsidomine is an exogenous source of nitric oxide for cardiovascular agents and vasodilator agents

Chemical Structure

Darsidomine
Darsidomine
CAS#137500-42-6

Theoretical Analysis

MedKoo Cat#: 412209

Name: Darsidomine

CAS#: 137500-42-6

Chemical Formula: C9H16N4O

Exact Mass: 196.1324

Molecular Weight: 196.25

Elemental Analysis: C, 55.08; H, 8.22; N, 28.55; O, 8.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Darsidomine; C87-3754; C 87-3754 C 87-3754
IUPAC/Chemical Name
3-(cis-2,6-Dimethylpiperidino)sydnone imine
InChi Key
VBBUFAXMBDEROK-OCAPTIKFSA-N
InChi Code
InChI=1S/C9H16N4O/c1-7-4-3-5-8(2)13(7)12-6-9(10)14-11-12/h6-8,10H,3-5H2,1-2H3/t7-,8+
SMILES Code
[NH-]C1=C[N+](N2[C@H](C)CCC[C@@H]2C)=NO1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 196.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Cui X, Sheng Z, Guo Z. [Role of endothelin and nitric oxide in early gut ischemia]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1999 Sep;15(5):360-2. Chinese. PMID: 11501100. 2: Demiryürek AT, Kennedy S, Wainwright CL, Wadsworth RM, Kane KA. Influence of nitric oxide on luminol-enhanced chemiluminescence measured from porcine- stimulated leukocytes. J Cardiovasc Pharmacol. 1997 Sep;30(3):332-7. doi: 10.1097/00005344-199709000-00010. PMID: 9300317. 3: Rizvi MA, Myers PR. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol. 1997 Jul;29(7):1779-89. doi: 10.1006/jmcc.1996.0480. PMID: 9236133. 4: Sun W, Wainwright CL. The role of nitric oxide in modulating ischaemia- induced arrhythmias in rats. J Cardiovasc Pharmacol. 1997 Apr;29(4):554-62. doi: 10.1097/00005344-199704000-00018. PMID: 9156367. 5: Chi OZ, Chang Q, Wang G, Weiss HR. Effects of nitric oxide on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Anesth Analg. 1997 Feb;84(2):370-5. doi: 10.1097/00000539-199702000-00024. PMID: 9024031. 6: Squadrito F, Altavilla D, Squadrito G, Campo GM, Ioculano M, Canale P, Rossi F, Saitta A, Caputi AP. Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock. Br J Pharmacol. 1996 Sep;119(1):23-8. doi: 10.1111/j.1476-5381.1996.tb15672.x. PMID: 8872352; PMCID: PMC1915735. 7: Pabla R, Buda AJ, Flynn DM, Blessé SA, Shin AM, Curtis MJ, Lefer DJ. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res. 1996 Jan;78(1):65-72. doi: 10.1161/01.res.78.1.65. PMID: 8603507. 8: Kubes P, Reinhardt PH, Payne D, Woodman RC. Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine. Am J Physiol. 1995 Jul;269(1 Pt 1):G34-41. doi: 10.1152/ajpgi.1995.269.1.G34. PMID: 7631799. 9: Chi OZ, Wei HM, Weiss HR. Effects of CAS 754, a new nitric oxide donor, on regional cerebral blood flow in focal cerebral ischemia. Anesth Analg. 1995 Apr;80(4):703-8. doi: 10.1097/00000539-199504000-00009. PMID: 7893021. 10: Lefer DJ. Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion. New Horiz. 1995 Feb;3(1):105-12. PMID: 7704591. 11: Guo JP, Siegfried MR, Lefer AM. Endothelial preserving actions of a nitric oxide donor in carotid arterial intimal injury. Methods Find Exp Clin Pharmacol. 1994 Jun;16(5):347-54. PMID: 7934313. 12: Kanwar S, Tepperman BL, Payne D, Sutherland LR, Kubes P. Time course of nitric oxide production and epithelial dysfunction during ischemia/reperfusion of the feline small intestine. Circ Shock. 1994 Mar;42(3):135-40. PMID: 8025978. 13: Payne D, Kubes P. Nitric oxide donors reduce the rise in reperfusion-induced intestinal mucosal permeability. Am J Physiol. 1993 Jul;265(1 Pt 1):G189-95. doi: 10.1152/ajpgi.1993.265.1.G189. PMID: 8393297. 14: Ivanova K, Schaefer M, Drummer C, Gerzer R. Effects of nitric oxide- containing compounds on increases in cytosolic ionized Ca2+ and on aggregation of human platelets. Eur J Pharmacol. 1993 Jan 4;244(1):37-47. doi: 10.1016/0922-4106(93)90057-g. PMID: 8420790. 15: Mülsch A, Hecker M, Mordvintcev PI, Vanin AF, Busse R. Enzymic and nonenzymic release of NO accounts for the vasodilator activity of the metabolites of CAS 936, a novel long-acting sydnonimine derivative. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jan;347(1):92-100. doi: 10.1007/BF00168778. PMID: 8383302. 16: Lefer AM, Siegfried MR, Ma XL. Protection of ischemia-reperfusion injury by sydnonimine NO donors via inhibition of neutrophil-endothelium interaction. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S27-33. PMID: 7504765. 17: Bassenge E, Zanzinger J. Effectiveness of an NO-releasing pirsidomine derivative on coronary conductance during long-term administration. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S22-6. PMID: 7504764. 18: La Rochelle CD, Dubois-Randé JL, Richard V, Hittinger L, Giudicelli JF, Berdeaux A. The role of NO release in the control of large and small coronary artery tone in conscious dogs. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S17-21. PMID: 7504763. 19: Schini VB, Bond R, Gao Y, Illiano S, Junquero DC, Mombouli JV, Nagao T, Smart F, Vanhoutte PM. The sydnonimine C87-3754 evokes endothelium-independent relaxations and prevents endothelium-dependent contractions in blood vessels of the dog. J Cardiovasc Pharmacol. 1993;22 Suppl 7:S10-6. PMID: 7504762. 20: Carey C, Siegfried MR, Ma XL, Weyrich AS, Lefer AM. Antishock and endothelial protective actions of a NO donor in mesenteric ischemia and reperfusion. Circ Shock. 1992 Nov;38(3):209-16. PMID: 1292885.